Squire Patton Boggs has added life sciences partner Todd Lorenz to its Intellectual Property & Technology Practice (IP&T) in San Francisco. Mr. Lorenz has extensive experience in the life sciences sector with a particular focus on patent prosecution, counseling, and IP transactions. He joins from Arnold & Porter.
“We represent major multinational pharmaceutical, medical device, and biotechnology companies, as well as start-up companies in the same fields,” said David Elkins, Squire Patton Boggs’ global Intellectual Property & Technology Practice Group head. “Todd’s dynamic background and deep expertise in the life sciences sector will continue our leadership in this area.”
“I am thrilled to be joining a firm with a clear commitment to patent prosecution at the highest level, and I look forward to adding to their already deep bench of legal and technical expertise,” said Todd. “Moving to Squire Patton Boggs has been transformative for me and my clients on multiple levels. The firm’s global footprint is more consistent with my practice and provides remarkable support and resources.”
Mr. Lorenz has over twenty-five years of experience in life sciences intellectual property law. His practice encompasses strategic patent prosecution and counseling along with related due diligence, opinion work, licensing, and litigation. He advises universities, clinical research centers, and emerging and established life science companies on all aspects of domestic and international patent procurement and enforcement in a broad range of technical areas including drug development (biologics & pharmaceuticals), drug delivery, digital health, diagnostics, industrial biotechnology, and laboratory instrumentation.
In addition to his legal practice, Mr. Lorenz is also Co-Founder and Chief Executive Officer of Myocept Inc., a biotech start-up developing a new generation of transcutaneous therapeutics. This experience gives him unique insights into the needs and challenges of emerging companies.
With an academic background in biology and engineering at Rensselaer Polytechnic Institute, clinical research experience in cancer immunotherapy at Harvard Medical School, and hands-on experience in drug development, formulation and commercialization at Myocept Inc., Mr. Lorenz brings a wide range of technical capabilities throughout the biotechnology and pharmaceutical arts to his law practice.
In August, Squire Patton Boggs enhanced its IP&T practice when partners Frank L. Bernstein, Vid R. Bhakar and Ronald S. Lemieux joined the firm in Palo Alto from intellectual property boutique Singularity LLP